HomeHEALTHAspirin Therapy Does Not Cut Risk in Non-Obstructive Coronary Artery Disease

Aspirin Therapy Does Not Cut Risk in Non-Obstructive Coronary Artery Disease

Aspirin therapy, as opposed to statin use, for non-obstructive coronary artery disease does not reduce major cardiovascular events, according to a new study published in the journal Radiology: Cardiothoracic Imaging.

Coronary artery disease is the most common type of heart disease, affecting roughly 6.7% of U.S. adults, according to the Centers for Disease Control and Prevention. Coronary artery disease occurs when there is a buildup of plaque in the arteries that supply blood to the heart. Coronary artery disease puts people at a higher risk for major adverse cardiovascular events, including heart attack and death.

Non-obstructive coronary artery disease occurs when there is less than 50% stenosis, or narrowing, of the coronary arteries due to plaque buildup. Coronary CT angiography (CCTA) is often recommended as a first-line test to detect plaque.

Medications called statins are commonly prescribed for patients who are diagnosed with non-obstructive coronary artery disease. Statins reduce the production of low-density lipoprotein (LDL) cholesterol and draw cholesterol out of plaque, therefore stabilizing the plaque and reducing the risk of it rupturing. Aspirin is another drug that is commonly recommended. However, not much research has been done to determine whether aspirin is effective at reducing major cardiovascular events in patients with non-obstructive coronary artery disease.

“While observational in nature, our data calls into question the value of initiating aspirin therapy following the diagnosis of non-obstructive coronary artery disease on a coronary CT angiography,” said study author Jonathan Leipsic, M.D., professor and head of the Department of Radiology at the University of British Columbia in Vancouver, Canada.

For the study, researchers used data from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) registry, a large, multinational database of patients who have undergone CCTA. A total of 6,386 patients (mean age 56.0 years, 52% men) who had either no detectable coronary plaque or non-obstructive coronary artery disease were selected. Patients with obstructive coronary artery disease that had 50% or greater stenosis were excluded. The mean follow-up period for selected patients was 5.7 years.

A total of 3,571 (56%) of the patients included in the study had no plaque and 2,815 (44%) had non-obstructive coronary artery disease. Non-obstructive coronary artery disease was associated with a 10.6% risk of all-cause mortality compared to 4.8% in patients without plaque.

Baseline aspirin and statin use were documented for both groups. In individuals with nonobstructive coronary artery disease, aspirin therapy was not associated with a reduction in major adverse cardiovascular events. Alternatively, statin use was associated with a significant reduction in cardiovascular events, including heart attack and death.

“Our findings build on prior analyses from the CONFIRM registry at 2.3-year follow-up which called into question the utility of aspirin in the setting of CCTA diagnosed atherosclerosis,” Dr. Leipsic said.

Neither aspirin therapy nor statin therapy improved clinical outcomes for patients with no detectable plaque. Aspirin therapy may still be beneficial in cases of high-risk plaque or high plaque burden, Dr. Leipsic said.

“Ultimately, further research is required to determine whether, and at what threshold, clinicians should consider prescribing aspirin for patients upon the identification of non-obstructive coronary artery disease on coronary CT angiography,” he said.


Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other Articles of Interest

Life Heater Reviews – URGENT Customer Alert! Reviews 2023, Is It Really Effective Or Scam

The portable heating gadget begins heating by setting the temperature and time on the top knobs, and soon it heats up to a very...

Toasty Heater Reviews For Sale, Price 2023 SCAM NEWS! Portable Heater

The Toasty Heater offers an easy installation method, which means you can start enjoying its benefits right away with no hassle or extra cost. The...

5 Ways to Use Credit Card Rewards for Travelling!

Are you a travel enthusiast with a keen eye for value for money? If so, you're in the right place. In today's digital age,...

Lessons from History Offer Profound Insight Into Challenges of Our Time | New Essays Celebrating Wisdom of the Past 2,500 Years Comprise Latest Book...

“In Rome 476, author David Parker awakens readers to the wisdom of 5th century Athens, 1st century Rome and 18th century Age of Enlightenment. Gleaning wisdom from the great thinkers and statesmen of the past, Parker’s mission is to educate fellow Americans in the historical, cultural, and founding principles of our country.” — Jeffrey Sikkenga, Executive Director, The Ashbrook Center

7 Ways a Personal Injury Lawyer Can Help You Settle Claims

Dealing with the aftermath of an injury can be overwhelming. You may be facing medical bills, lost wages, and the stress of recovery. In...

The Ultimate Guide on Where To Buy Delta 9 Vape Pens

Vaping has become a popular way of relaxing and enjoying the benefits of Delta 9 THC. Delta 9 THC is the chemical compound responsible...

By using this website you agree to accept Medical Device News Magazine Privacy Policy